US › Healthcare

Biovie Inc (BIVI)

US · Healthcare · Biotechnology

$1.83+12.96%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-5.3M
Profit YoY
-89.0%
EPS
$-0.70

Key statistics

Market cap
$11.5M
Forward P/E
0.0
P/B
0.74
Book value
$2.07
EPS (TTM)
$-3.79
52-week high
$6.01
52-week low
$1.06
50-day MA
$1.69
200-day MA
$1.49
Beta
0.67

Analyst view

Analysts rate Biovie Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $5.25.

Shareholding

Insiders
0.30%
Institutions
14.28%

Largest institutional holders

FundStake
Diametric Capital, LP4.91%
Springbok Capital Management, LLC1.22%
Geode Capital Management, LLC1.12%
Vanguard Capital Management, LLC1.11%
Morgan Stanley - Brokerage Accounts1.00%
Philadelphia Trust Co0.99%
Renaissance Technologies Corp0.90%
Citadel Advisors Llc0.60%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Biovie Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.